GLP-1 receptor agonists are incretin mimetic drugs commonly used for glycemic control in type 2 diabetes. They work by stimulating the release of insulin from pancreatic beta cells and suppressing glucagon secretion. GLP-1 receptor agonists provide effective glycemic control along with weight loss benefits and low risk of hypoglycemia. The growing prevalence of diabetes and obesity has fueled the demand for these drugs in recent years.

The global GLP-1 receptor agonist Market is estimated to be valued at US$ 14319.85 Mn in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends
The increasing awareness about glycemic control and lifestyle management among diabetic patients has boosted the adoption of GLP-1 receptor agonists. These drugs minimize blood sugar fluctuations and aid weight loss, thereby improving quality of life. As a result, they have gained popularity as an effective treatment option for achieving optimal glycemic targets and managing obesity. Additionally, technological advancements have led to development of novel delivery systems such as oral formulations, long-acting injections, and implants. This in turn is supporting the market growth over the forecast period.

Segment Analysis
The global GLP-1 Receptor Agonist market is dominated by subcutaneous injection segment which holds around 95% market share. This is because subcutaneous injection is the conventional and preferred mode of administration of GLP-1 receptor agonists owing to its effectiveness and ease of use. Oral formulations segment is in the nascent stage and yet to gain traction.

Key Takeaways
The Global GLP-1 Receptor Agonist Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global GLP-1 receptor agonist Market is estimated to be valued at US$ 14319.85 Mn in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023 to 2030.

North America currently dominates the market due to presence of major players and higher adoption of therapeutic injectable drugs. However, Asia Pacific region is expected to showcase fastest growth owing to rising incidence of diabetes and growing healthcare infrastructure in emerging economies of China and India. Increasing diabetes cases coupled with improving access to healthcare are driving the market growth in Asia Pacific region.

Key players
Key players operating in the GLP-1 Receptor Agonist market are Auto Power, Volmac Engg. (P) Limited, Club Car, LLC, Carrieall Car Private Limited, Speedways Electric, GDrive Golf Carts, Maini Material Movement Pvt. Ltd., Nebula Automotive Pvt. Ltd., Prevalence Ltd., and Yamaha Golf-Car Company.

Get more insights on this topic:

https://www.feedsfloor.com/other/glp-1-receptor-agonist-market-estimated-witness-high-growth-owing-rising-prevalence-diabetes